These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 36731272)
1. PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism. Lin H; Han H; Yang M; Wen Z; Chen Q; Ma Y; Wang X; Wang C; Yin T; Wang X; Lu G; Chen H; Qi J; Yang Y Eur J Med Chem; 2023 Mar; 249():115166. PubMed ID: 36731272 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel modified dual-target shikonin derivatives for colorectal cancer treatment. Ma Y; Lai X; Wen Z; Zhou Z; Yang M; Chen Q; Wang X; Mei F; Yang L; Yin T; Sun S; Lu G; Qi J; Lin H; Han H; Yang Y Bioorg Chem; 2023 Oct; 139():106703. PubMed ID: 37399615 [TBL] [Abstract][Full Text] [Related]
3. Novel shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1/PDHC axis. Chen Q; Han H; Lin F; Yang L; Feng L; Lai X; Wen Z; Yang M; Wang C; Ma Y; Yin T; Lu G; Lin H; Qi J; Yang Y Life Sci; 2022 Dec; 310():121077. PubMed ID: 36244412 [TBL] [Abstract][Full Text] [Related]
4. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway. Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397 [TBL] [Abstract][Full Text] [Related]
5. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer. Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Yang Z; Zhang SL; Hu X; Tam KY Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498 [TBL] [Abstract][Full Text] [Related]
7. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507 [TBL] [Abstract][Full Text] [Related]
8. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220 [TBL] [Abstract][Full Text] [Related]
9. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409 [TBL] [Abstract][Full Text] [Related]
10. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
11. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022 [TBL] [Abstract][Full Text] [Related]
12. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy. Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133 [TBL] [Abstract][Full Text] [Related]
13. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201 [TBL] [Abstract][Full Text] [Related]
14. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway. Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778 [TBL] [Abstract][Full Text] [Related]
15. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757 [TBL] [Abstract][Full Text] [Related]
16. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET. Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446 [TBL] [Abstract][Full Text] [Related]
17. [Combination of shikonin and gefitinib reverses drug resistance in human non-small cell lung cancer and its mechanism]. Ai XY; Hou XF; Feng NP Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(1):175-184. PubMed ID: 38403350 [TBL] [Abstract][Full Text] [Related]
18. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo. Zhang K; Wang L; Wei A; Jia X; Liu X Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855 [TBL] [Abstract][Full Text] [Related]
19. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210 [TBL] [Abstract][Full Text] [Related]
20. Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer. Chen Z; Huang KY; Ling Y; Goto M; Duan HQ; Tong XH; Liu YL; Cheng YY; Morris-Natschke SL; Yang PC; Yang SL; Lee KH J Nat Prod; 2019 Nov; 82(11):3065-3073. PubMed ID: 31718182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]